UBE3A and Angelman syndrome: In particular, topoisomerase inhibitors have recently been used to reactivate the silenced paternal Ube3a gene, which encodes a ubiquitin E3 ligase, to compensate for the deleted maternal Ube3a in Angelman syndrome (AS).